ArticleACS nano2017
Nanoporous Immunoprotective Device for Stem-Cell-Derived β-Cell Replacement Therapy.
Article in ACS nano, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 91 citations in OpenAlex.
- Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering.Diabetes/metabolism research and reviews · 2026Review
- Reconstructing the Islets: Advances in 3D Pancreatic Organoid Models for Functional β-Cell Replacement.International journal of molecular sciences · 2026Review
- Review
- Anti-CD3 microporous annealed particle hydrogel protects stem cell derived beta cells from autoreactive T cells.bioRxiv : the preprint server for biology · 2025Article
- Immune Evasion in Stem Cell-Based Diabetes Therapy-Current Strategies and Their Application in Clinical Trials.Biomedicines · 2025Review
- Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead.Nature reviews. Endocrinology · 2025Review
- Supporting islet function in a PVDF membrane based macroencapsulation delivery device by solvent non-solvent casting using PVP.PloS one · 2025Article
- Week-long normoglycaemia in diabetic mice and minipigs via a subcutaneous dose of a glucose-responsive insulin complex.Nature biomedical engineering · 2024Article
- Silicone cryogel skeletons enhance the survival and mechanical integrity of hydrogel-encapsulated cell therapies.Science advances · 2024Article
- A novel bioartificial pancreas fabricated via islets microencapsulation in anti-adhesive core-shell microgels and macroencapsulation in a hydrogel scaffold prevascularized in vivo.Bioactive materials · 2023Article
- Replenishable prevascularized cell encapsulation devices increase graft survival and function in the subcutaneous space.Bioengineering & translational medicine · 2023Article
- Engineering the next generation of cell-based therapeutics.Nature reviews. Drug discovery · 2022Review
- Differential Function and Maturation of Human Stem Cell-Derived Islets After Transplantation.Stem cells translational medicine · 2022Article
- A Safe, Fibrosis-Mitigating, and Scalable Encapsulation Device Supports Long-Term Function of Insulin-Producing Cells.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Engineering islets from stem cells for advanced therapies of diabetes.Nature reviews. Drug discovery · 2021Review
- Localized drug delivery graphene bioscaffolds for cotransplantation of islets and mesenchymal stem cells.Science advances · 2021Article
- A therapeutic convection-enhanced macroencapsulation device for enhancing β cell viability and insulin secretion.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Biomaterials for Cell-Surface Engineering and Their Efficacy.Journal of functional biomaterials · 2021Review
- Modulating the foreign body response of implants for diabetes treatment.Advanced drug delivery reviews · 2021Review
- A nanofibrous encapsulation device for safe delivery of insulin-producing cells to treat type 1 diabetes.Science translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Encapsulation of human embryonic stem-cell-differentiated beta cell clusters (hES-βC) holds great promise for cell replacement therapy for the treatment of diabetics without the need for chronic systemic immune suppression. Here, we demonstrate a nanoporous immunoprotective polymer thin film cell encapsulation device that can exclude immune molecules while allowing exchange of oxygen and nutrients necessary for in vitro and in vivo stem cell viability and function. Biocompatibility studies show the device promotes neovascular formation with limited foreign body response in vivo. The device also successfully prevented teratoma escape into the peritoneal cavity of mice. Long-term animal studies demonstrate evidence of engraftment, viability, and function of cells encapsulated in the device after 6 months. Finally, in vivo study confirms that the device was able to effectively immuno-isolate cells from the host immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.